Research Topics
| Stephen CaldwellSummaryAffiliation: University of Virginia Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Coagulation disorders and hemostasis in liver disease: pathophysiology and critical assessment of current managementStephen H Caldwell
University of Virginia, Digestive Health Center of Excellence, GI Hepatology Division, Charlottesville, VA 22908 0705, USA
Hepatology 44:1039-46. 2006....
Gastric varices: is there a role for endoscopic cyanoacrylates, or are we entering the BRTO era?Stephen Caldwell
Division of Gastroenterology and Hepatology, University of Virginia Medical Center, Charlottesville, Virginia 22908 0708, USA
Am J Gastroenterol 107:1784-90. 2012..Here, I provide a perspective based on existing literature, 15 years of experience with various cyanoacrylates, and 4 years of experience with BRTO...- Cryptogenic cirrhosis: clinical characterization and risk factors for underlying diseaseS H Caldwell
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA
Hepatology 29:664-9. 1999..Although there is some diversity that indicates more than one cause, our findings suggest that NASH plays an under-recognized role in many patients with cryptogenic cirrhosis, most of whom are older, type 2 diabetic and obese females... - Obesity and hepatocellular carcinomaStephen H Caldwell
Division of Gastroenterology and Hepatology, University of Virginia Health System, P O Box 800708, Charlottesville, Virginia 22908 0708, USA
Gastroenterology 127:S97-103. 2004.... - Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitisStephen H Caldwell
Division of GI Hepatology, Department of Internal Medicine, University of Virginia, Charlottesville, VA 22908 0708, USA
Hepatology 49:1888-95. 2009..We speculate that such transitions result from microenvironmental changes within the mitochondria and carry therapeutic implications, especially in regard to dietary manipulations of mitochondrial lipid composition... - Coagulation disorders and bleeding in liver disease: future directionsStephen H Caldwell
GI Hepatology Division, Digestive Health Center of Excellence, University of Virginia Medical Center, Box 800708, Charlottesville, VA 22908 0708, USA
Clin Liver Dis 13:155-7. 2009..The challenge lies ahead... - Therapy of NAFLD: insulin sensitizing agentsStephen H Caldwell
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908 0708, USA
J Clin Gastroenterol 40:S61-6. 2006..Neither agent has been FDA approved for treating NAFLD, but existing studies have provided much hope for incorporating these medications into NAFLD management strategies in selected patients... - Treating NAFLD: future prospectsStephen H Caldwell
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908-0708, USA
J Clin Gastroenterol 40:S67-8. 2006 - The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitisStephen H Caldwell
Gastrointestinal Hepatology Division, Digestive Health Center of Excellence, University of Virginia, Charlottesville, VA 22908, USA
Hepatology 46:1101-7. 2007..Whether these are adaptive or pathological remains unknown, and further studies are warranted to assess hepatic mitochondrial function during thiazolidinedione therapy for NASH... - Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?Stephen H Caldwell
Division of GI Hepatology, Digestive Health Center of Excellence, University of Virginia, Charlottesville, Virginia 22908 0708, USA
J Gastroenterol Hepatol 22:S11-9. 2007.... - Enbucrilate for gastric varices: extended experience in 92 patientsS H Caldwell
GI Hepatology Division, Digestive Health Center of Excellence, University of Virginia Medical Center, Charlottesville, VA 22908 0708, USA
Aliment Pharmacol Ther 26:49-59. 2007..We assessed N-2-butyl-cyanoacrylate (enbucrilate) in 92 patients with gastric variceal bleeding under an FDA-approved investigation. These results extend our prior report of the first 44 patients... - Mitochondria in nonalcoholic fatty liver diseaseStephen H Caldwell
Division of Gastroenterology and Hepatology, University of Virginia Health System, PO Box 800708, Charlottesville, VA 22908, USA
Clin Liver Dis 8:595-617, x. 2004..The prominent role of mitochondrial dysfunction in NAFL provides a new and exciting paradigm in which to view this disorder, its complications, and potential dietary and pharmacologic intervention... - NASH and cryptogenic cirrhosis: a histological analysisStephen H Caldwell
Division of Gastroenterology and Hepatology, Digestive Health Center, University of Virginia, Charlottesville, Virginia 22908, USA
Ann Hepatol 8:346-52. 2009.... - Imaging and clinical characteristics of focal atrophy of segments 2 and 3 in primary sclerosing cholangitisS H Caldwell
The University of Virginia, Department of Internal Medicine, Charlottesville, United States of America
J Gastroenterol Hepatol 16:220-4. 2001..We examined 44 consecutive PSC patients to determine the incidence and clinical characteristics of this abnormality, and to correlate imaging studies with the gross appearance... - Is exercise an effective treatment for NASH? Knowns and unknownsStephen Caldwell
The University of Virginia, Division of GI Hepatology, Charlottesville, Virginia, Charlottesville, VA 22908 0708, USA
Ann Hepatol 8:S60-6. 2009.... 
Hepatocellular ballooning in NASHStephen Caldwell
GI Hepatology, University of Virginia, Charlottesville, VA, USA
J Hepatol 53:719-23. 2010..Fat droplets are emerging as important organelles in cell metabolism. To address a possible relation between fat droplets and ballooning, we studied fat staining, H&E, and keratin 18 staining in human NASH...- Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapyVanessa M Shami
Division of Gastroenterology and Hepatology, The University of Virginia, Charlottesville, VA 22908, USA
Liver Transpl 9:138-43. 2003..Our preliminary experience supports the need for further studies to define the optimal dosing, safety, and efficacy of rFVIIa in patients with FHF... - Cryptogenic cirrhosis: what are we missing?Stephen Caldwell
Digestive Health Center, GI Hepatology Division, University of Virginia Health Science Center, Charlottesville, VA 22908 0708, USA
Curr Gastroenterol Rep 12:40-8. 2010..In this article, we review these associations as well as a proposed classification system for cryptogenic cirrhosis and other lesser known genetic and syndromic associations that warrant consideration when evaluating these individuals... - The natural history of non-alcoholic fatty liver diseaseStephen Caldwell
Division of Gastroenterology and Hepatology, Digestive Health Center of Excellence, University of Virginia Health System, Charlottesville, VA 22908, USA
Dig Dis 28:162-8. 2010..Meanwhile, the relationship between these comorbidities will increasingly lead to patients with both coronary disease or malignancy and NASH-related cirrhosis presenting clinicians with a very challenging set of problems in coming years... - Recombinant activated factor VII (rFVIIa) as a hemostatic agent in liver disease: a break from convention in need of controlled trialsStephen H Caldwell
Divisions of Gastroenterology and Hepatology, The University of Virginia Health Sciences Center, Box 800708, Charlottesville, VA 22908, USA
Hepatology 39:592-8. 2004..Herein we review the mechanism of action of this agent, report the clinical applications in patients with liver disease, address the limitations and risks associated with the drug, and discuss the issue of its cost-effectiveness... - The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver diseaseStephen H Caldwell
The Division of Gastroenterology and Hepatology, Box 800708, University of Virginia Health System, Charlottesville, VA 22908-0708, USA
J Hepatol 40:578-84. 2004 - The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biologyStephen Caldwell
Division of Gastroenterology and Hepatology, Digestive Health Center of Excellence, University of Virginia Health System, P O Box 800708, Charlottesville, VA 22908 0708, USA
J Gastroenterol 44:96-101. 2009..The relative efficacy of these agents will likely depend on the biochemical pathways active in a given hepatocellular malignancy. This, in turn, is likely to be related to the epidemiological associations of HCC... - The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitisTri H Le
Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, Virginia, USA
Hepatology 39:1423-9. 2004..In this study, their presence did not seem to correlate with the light microscopic injury pattern represented by ballooned hepatocytes or degree of oxidative stress defined by immunostaining for 4-hydroxynonenal... - Statins in liver disease: a molehill, an iceberg, or neither?Curtis K Argo
Department of Medicine, Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA, USA
Hepatology 48:662-9. 2008..Research using histological endpoints is urgently needed to determine the indications and contraindications of this extraordinary class of agents in patients with chronic liver disease... - Accelerated treatment using intensity-modulated radiation therapy plus concurrent capecitabine for unresectable hepatocellular carcinomaAlyson McIntosh
Department of Radiation Oncology, University of Virginia Health System, Charlottesville, Virginia, USA
Cancer 115:5117-25. 2009..In this study, the authors investigated the feasibility, toxicity, and efficacy associated with intensity-modulated radiation therapy (IMRT) and concurrent, chronomodulated capecitabine in the treatment of unresectable HCC... - Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitisCurtis K Argo
Division of Gastroenterology and Hepatology, University of Virginia Health System, JPA and Lee St, MSB 2091, PO Box 800708, Charlottesville, VA, USA
J Hepatol 51:371-9. 2009.... - Thiazolidinediones for the treatment in NASH: sustained benefit after drug discontinuation?Curtis K Argo
Division of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA 22908 0708, USA
J Clin Gastroenterol 43:565-8. 2009..A recent clinical study suggests that relapse of NASH pathophysiology is inevitable and that lifelong therapy may be needed to maintain histologic response... - Epidemiology and natural history of non-alcoholic steatohepatitisCurtis K Argo
Division of Gastroenterology and Hepatology, University of Virginia Health System, 1335 Lee Street, MSB 2091, Box 800708, Charlottesville, VA 22908 0708, USA
Clin Liver Dis 13:511-31. 2009..This article describes the epidemiology and natural history of this disorder. It also describes current diagnostic and treatment methods and describes future implications NAFLD may have... - The role of anti-fibrinolytics, rFVIIa and other pro-coagulants: prophylactic versus rescue?Neeral L Shah
Division of Gastroenterology and Hepatology, West Complex Box 800708, Department of Gastroenterology and Hepatology, University of Virginia, Charlottesville, VA 22908, USA
Clin Liver Dis 13:87-93. 2009.... - Regional citrate anticoagulation in critically ill patients with liver and kidney failureRasheed A Balogun
Division of Nephrology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia, USA
J Nephrol 25:113-9. 2012..The study compares the circuit lifespan and metabolic complications using RCA for CRRT at varying levels of liver dysfunction... - Subacute liver failure in obese womenStephen H Caldwell
Department of Internal Medicine, University of Virginia, Charlottesville 22908-0708, USA
Am J Gastroenterol 97:2058-62. 2002..We propose that obesity-related liver disease may infrequently present as severe, subacute illness... - Clear cell hepatocellular carcinoma arising 25 years after the successful treatment of an infantile hepatoblastomaJeffrey Basile
Department of Medicine, University of Virginia Medical Center, Charlottesville, USA
Ann Hepatol 9:465-7. 2010..Further knowledge of liver tumorigenesis will help elucidate the complicated genetic, molecular, and environmental factors involved in the development of these two rare hepatic malignancies... - Therapy of NAFLD: antioxidants and cytoprotective agentsCharissa Y Chang
Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Virginia Health System, Charlottesville, VA 22908-0708, USA
J Clin Gastroenterol 40:S51-60. 2006..Particular promise may exist in the use of these agents in combination therapy with ones that target other aspects in the pathogenesis of NAFLD, such as insulin-sensitizing agents... - Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolismPatrick G Northup
Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia, USA
Am J Gastroenterol 101:1524-8; quiz 1680. 2006..Low serum albumin was strongly predictive of increased risk for developing VTE, independent of international normalized ratio or platelet count. Serum albumin deficiency may indicate low levels of endogenous anticoagulants... - Severe prolongation of the INR in spur cell anemia of cirrhosis: true-true and related?Vinay Sundaram
Department of Internal Medicine, Division of Gastroenterology and Hepatology, University of Virginia Health System, Charlottesville, Virginia 22908 0708, USA
Dig Dis Sci 51:1203-5. 2006 - Nonalcoholic steatohepatitis: summary of an AASLD Single Topic ConferenceBrent A Neuschwander-Tetri
Division of Gastroenterology and Hepatology, Saint Louis University School of Medicine, MO 63110, USA
Hepatology 37:1202-19. 2003.... - Is NASH underdiagnosed among African Americans?Stephen H Caldwell
Department of Internal Medicine, University of Virginia, Charlottesville 22908 0708, USA
Am J Gastroenterol 97:1496-500. 2002..Because obesity and type 2 diabetes are prevalent among African American females by the 5th and 6th decades, one would expect an increased number of African Americans among patients with NASH and cryptogenic cirrhosis... - Treatment of primary liver tumors with Yttrium-90 microspheres (TheraSphere) in high risk patients: analysis of survival and toxicitiesKelli A Reardon
Department of Radiation Oncology, University of Virginia, Charlottesville, VA 22908 0383, USA
Technol Cancer Res Treat 8:71-7. 2009..This study concluded that Yttrium-90 is a low-toxicity, outpatient alternative for individuals with liver cancer and without many options. The maximal value, however, may lie in the treatment of low-risk patients... - The role of recombinant factor VIIa in liver transplantationRobert J Porte
Liver Transpl 11:872-4. 2005 - N-2-butyl-cyanoacrylate for bleeding gastric varices: a United States pilot study and cost analysisBruce D Greenwald
Division of Gastroenterology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
Am J Gastroenterol 98:1982-8. 2003..This is believed to result largely from avoidance of shunt interventions. CONCLUSIONS: Cyanoacrylate treatment of gastric varices is safe, clinically effective, and cost effective... - Divergent effects of peroxisome proliferator-activated receptor-gamma ligands in human and mouse nonalcoholic steatohepatitisStephen H Caldwell
Hepatology 46:285-7. 2007 - Enlarged hepatocytes in NAFLD examined with osmium fixation: does microsteatosis underlie cellular ballooning in NASH?Stephen H Caldwell
Am J Gastroenterol 101:1677-8. 2006 - Yo jyo hen shi ko, a novel Chinese herbal, prevents nonalcoholic steatohepatitis in ob/ob mice fed a high fat or methionine-choline-deficient dietVicência Mara Rodrigues de Lima
Department of Gastroenterology LIM 07, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
Liver Int 27:227-34. 2007..The aim of this study was to evaluate the role of the effect of YHK in experimental NASH... - The liver and statin drug therapy: uncertain navigation in the sea of risk-benefitStephen H Caldwell
Pharmacoepidemiol Drug Saf 12:303-6. 2003 - Treatment of bleeding gastric varicesPatrick G Northup
J Gastroenterol Hepatol 20:1631-3. 2005 - Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosisAbdullah M S Al-Osaimi
Hepatology 41:943. 2005
Research Grants
- Omega-3 Fish Oil for Nonalcoholic SteatohepatitisStephen Caldwell; Fiscal Year: 2007....